Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.
Center for Advanced Reproductive Services, Department of Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut.
Fertil Steril. 2019 Aug;112(2):258-265. doi: 10.1016/j.fertnstert.2019.03.040. Epub 2019 May 15.
To evaluate differences in euploidy rates between IVF cycles triggered with either GnRH agonist (GnRHa) or hCG.
Retrospective cohort study.
University-affiliated fertility center.
PATIENT(S): A total of 366 patients performing 539 IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A).
INTERVENTION(S): Gonadotropin-releasing hormone agonist or hCG trigger of oocyte maturation during IVF cycles.
MAIN OUTCOME MEASURE(S): Rate of euploid embryos.
RESULT(S): Patients in the GnRHa trigger arm were younger, with a lower body mass index and higher antimüllerian hormone level, and they had a higher number of oocytes retrieved and embryos biopsied. Euploid rate per embryo biopsied was higher after GnRHa trigger than after hCG trigger (37.8% ± 2.1% vs. 30.3% ± 1.8%), but multivariate regression analysis controlling for potential confounding factors did not show any differences between the two groups. Moreover, the euploid rate per oocyte retrieved was not significantly different overall (GnRHa vs. hCG: 33.9% ± 2.2% vs. 28.0% ± 1.9%). The anticipated decline in the rate of euploid embryos per oocyte retrieved went from 15.8% ± 1.2% for age <35 years to 4.3% ± 0.9% for patients aged ≥41 years. There were no significant differences between the two groups after stratifying by age and controlling for PGT-A testing modality.
CONCLUSION(S): Both GnRHa and hCG trigger result in comparable euploid rates. Trigger with GnRHa should therefore be considered a valid option for trigger modality in freeze-all PGT-A cycles, in view of its demonstrated effectiveness and known safety enhancement.
评估使用 GnRH 激动剂(GnRHa)或 hCG 触发体外受精(IVF)周期时的整倍体率差异。
回顾性队列研究。
大学附属生育中心。
共 366 名患者进行了 539 个 IVF 周期,这些周期均采用胚胎植入前遗传学检测非整倍体(PGT-A)。
IVF 周期中促性腺激素释放激素激动剂或 hCG 触发卵母细胞成熟。
整倍体胚胎率。
GnRHa 触发组的患者更年轻,体重指数更低,抗苗勒管激素水平更高,取卵数和胚胎活检数也更多。GnRHa 触发后活检胚胎的整倍体率高于 hCG 触发(37.8%±2.1%比 30.3%±1.8%),但多变量回归分析控制潜在混杂因素后,两组间无差异。此外,总体上每个卵母细胞的整倍体率无显著差异(GnRHa 比 hCG:33.9%±2.2%比 28.0%±1.9%)。预计每个卵母细胞获得的整倍体胚胎率从<35 岁患者的 15.8%±1.2%下降到≥41 岁患者的 4.3%±0.9%。按年龄分层并控制 PGT-A 检测方式后,两组间无显著差异。
GnRHa 和 hCG 触发均导致相似的整倍体率。鉴于 GnRHa 已被证实的有效性和已知的安全性增强作用,GnRHa 触发应该被视为冷冻所有 PGT-A 周期中触发方式的有效选择。